In five patients with hemophilia B and detectable Factor IX antigen, altered reactivity to a specific polyclonal antibody fraction or monoclonal anti-Factor IX antibodies was noted.
Introduction
Hemophilia B is an X-linked bleeding disorder caused by deficiency of Factor IX clotting activity in patients' bloods. Genetic heterogeneity is reflected by varied clinical severity and different levels of Factor IX activities and antigen found in plasmas of affected members from different families (1) . The known molecular defects of Factor IX in patients with hemophilia B are likewise heterogeneous, including gene deletions, an insertion, and point mutations (2) . Because of the lack of a selective advantage of hemophilia, it can be assumed that each family has a "private" defect (3). Occasionally, patients from different families will have the same defect (e.g., references [4] [5] [6] , suggesting the presence of mutation hot spots.
Recently, additional point mutations are being defined by using the polymerase chain reaction and sequencing the amplified DNA fragments (e.g., references 7-9). In the current study, amplification and DNA sequencing were performed on selected regions of the Factor IX gene. These regions were identified because of decreased binding of the respective hemophilic Factor IX proteins to antibodies known to react with epitopes in distinct sequence regions of the Factor IX protein.
Each patient had detectable hemophilic Factor IX proteins that were characterized immunochemically. Three distinct point mutations in five different families were identified.
Methods
Factor IX assays. Factor IX clotting activities were determined in the one-stage clotting assay using deficient substrate plasmas as described (1) . Factor IX antigen levels were from immunoradiometric assays using fractions of polyclonal rabbit anti-Factor IX sera (10) . For some assays, MAbs were used as the solid phase (adsorbed) reagent with labeled polyclonal rabbit anti-Factor IX fractions as the second antibody. MAbs included ClOD (1 1), 2D5 provided by Howard Reisner, Chapel Hill, NC (12) , and A-l and A-7 from Kenneth Smith, Albuquerque, NM (13) .
Purification and electrophoresis ofhemophilic Factor IXs. Heparinized plasma samples (5-15 ml) were immunoaffinity purified over a column (1 ml bed volume for 1-5 ml plasma) of CH-Sepharose to which 1 mg/ml rabbit calcium-dependent polyclonal antibody had been attached. Columns were equilibrated in 5 mM CaCI2 and the partially purified Factor IX eluted in 10 mM EDTA. For the propositus in family B-2, a 500-ml sample of plasma was available and his Factor IX was purified as described for Factor IXvancouver (14) . Briefly, the barium citrate eluate was immunoaffinity purified and then chromatographed on a mono-Q column. This material was then radioiodinated as described (1) . PAGE in SDS was performed as described (15) for partially purified patient vs. normal Factor IXs which were immunoblotted, or by transfer to nitrocellulose and direct radioautography for '251-labeled Factor IXs.
DNA samples, purification, and polymerase chain reaction (PCR).' DNA was extracted from leukocytes prepared from 10-20 ml whole blood anticoagulated with either heparin or EDTA and genomic DNA isolated as described (16) . The PCR was performed according to a modified method described by Saiki et al. (17) with an automatic DNA thermal cycler (Perkin Elmer-Cetus, Norwalk, CT). The conditions were set at 94°C for I min for denaturation, followed by 1.5 min at 50°C for annealing, and 2 min at 70°C for extending. A total of 30 cycles were performed. Three sets ofprimers (20-25 mers) were used to amplify exon II, exon IV, and the 5' half of exon VIII and their exon/ intron junctions. The locations and directions of the primers are shown in Fig. 1 . The lengths of the amplified fragments are 338 bp for exon II, 273 bp for exon IV, and 363 bp for exon VIII. DNA sequencing. The amplified DNA fragments were purified and subjected to direct nucleotide sequencing by the dideoxy chain termination method of Sanger et al. (18) . The generations. There was no living ancestor available for testing in any of the five families who represented a potential origin of the mutation.
Results
Immunoassays on hemophilic Factor IXproteins. Table I presents the Factor IX levels as clotting activity, total antigen, and antigen by three immunoradiometric assays with more specific antibodies. Patients from the six different families tested were grouped according to reactivity in the specific assays where the epitopes primarily reflect the Gla-domain (A), the first epidermal growth factor-like region (B), and the amino-terminal half of the heavy chain of Factor IXa (C). It should be noted that patients from each ofthese families had decreased reactivity in a single, specific assay with comparable levels in other assays. None of the other 109 patients, nor a separate series of 35 normal Caucasian male donors, had > 15% difference in any of their specific vs. total clottable Factor IX antigen levels.
The patient in family A had mildly reduced total Factor IX antigen with levels from the calcium-dependent assay of only one-third of his total antigen level. In a separate immunoradiometric assay using as a solid-phase A-1 and as labeled antibody A-7 MAbs, where the latter is dependent on divalent metal ions (13, 15) , his plasma level was 11 U/dl. This value was the same as determined for the polyclonal, calcium-dependent system (Table I) . The epitopes to which this antibody fraction binds, in the presence of calcium, are on the light chain of Factor IXa and reactivity is reduced in vitamin K disorders (15, 19) . It was predicted that this patient's defect would involve the Gla domain, and, because of his severity and the relative importance of the more amino-terminal Gla residues of prothrombin, that the defect would be within exon II.
The B group of families were not known to be related and all had mild hemophilia with mildly reduced Factor IX anti- (20) . A different immunoradiometric assay using solid-phase A-1 antibody was used to test for the dimorphism at residue 148 (10). All patients in Table I except for the two in family B-2 were strongly reactive, indicating they had the Thr-148 allele. Hemophilia in the two patients from family B-2 was associated with the Ala-148 allele (e.g., markedly decreased binding to solid-phase A-I MAb).
Although not known to be related, and from different ethnic and geographic lineage, the two patients, C-I and C-2, had similar low levels ofFactor IX activity and antigen and moder-
ately severe bleeding tendencies. As previously reported (1 1), they lacked detectable binding to ClOD, a MAb, which involves residues coded within the last 15 codons of exon VI, exon VII's 28 codons, and the first 77 codons of exon VIII (12) . Over half of these exon VIII coding sequences are in variable regions of the heavy chain of Factor IXa (21). Therefore, it was predicted that exon VIII would most likely contain the substitution(s) in these patients.
Immunoelectrophoresis of hemophilic proteins. All patients' partially purified Factor IXs migrated the same as normal Factor IX on immunoblots after PAGE (7.5%) in SDS. In addition to these results with partially purified Factor IXs, a purified sample from two patients in family B-I and one from the affected member C-2 also showed normal mobility. After Factor XIa cleavage, the isolated, radiolabeled hemophilic Factor IX from patient B-2 was electrophoresed. Activation cleavages occurred to a comparable extent as with normal Factor IX and migration of both heavy and light chains was indistinguishable from the normal control.
Single point mutations and derived amino acid substitution. From the amplified patient DNA fragments, single point mutations were identified in patients of all five families tested. For the patient in family A, a G to A mutation (see Fig. 2 a) was found at nucleotide 6,454 in exon II. This changed the codon for Glu-27 to Lys, at a residue that is normally gamma carboxylated. For two patients in family B-I and the propositus in B-2, G to A transitions (Fig. 2 b) were found at nucleotide sequence 10,430 in exon IV. This will change Gly-60 of the normal Factor IX sequence to Ser in these patients. For families C-I and C-2, a G to A transition was found at nucleotide 30,864 (Fig. 2 c) . This mutation changes Arg-248 to Gln in the patients' Factor IXs. patients with each of these three defects were otherwise as previously reported for normal Factor IX (22) .
Discussion
A group of unrelated hemophilia B families was studied with affected members showing altered immunoreactivity to one of three specific antibody preparations. A strategy was devised to localize their defects, predicting that point mutations would be found within or near the regions of Factor IX that bind these antibodies in exons II, IV, or VIII among the five families tested. After PCR amplification and direct sequencing of the selected fragments of the gene, a single base transition in the suspected exon was found in each case. In patient A the defect was associated with severe hemophilia and altered calcium-binding properties. The Glu-27 to Lys mutation is designated Factor IXSeatd 3. Two patients with nucleotide changes in this region were recently reported by Koeberl et al. (23) . In one, Arg-29 was Gln in a patient with 30 U/dl Factor IX clotting activity (mild), and in a second, Glu-33 was substituted for Asp, producing a moderately severe bleeding tendency. In vitamin K-dependent proteins, the homologue of Glu-27 is invariant and becomes a Gla residue; a Glu-33 homologue is not present in Factor VII or protein C, but is also a Gla in the other vitamin K-dependent proteins. Characterization of abnormal prothrombin fractions from a patient with a congenital vitamin K-deficient state (24) The patients in group B and two others from North Carolina were found to have low reactivity to a MAb known to bind to the first epidermal growth factor-like region of Factor IX (20) . The derived substitution of a Gly to Ser at amino acid 60 was found in patients from families B-l and B-2 (see Fig. 2 b) and the two North Carolina patients, where the defect was designated as Factor IXD,,r (9) . The presence of a different polymorphism (Ala-148 vs. Thr) in the patients in family B-2 strongly argues for theirs, at least, being due to an independent mutation. It is otherwise possible that mutations leading to mild bleeding tendencies receive little selective pressure from the environment and thus persist and accumulate in the population.
In comparing sequences in the first growth factor-like region, residue 61 is Ile in the mouse instead of Ser in the human. The only other different amino acids are at residues 67, 74, 75, and 80 (26) . The absence of a Pro-74 in murine Factor IX should lead to a significant conformational difference in the third disulfide loop-like structure; it is possible that the epitope involves both this site and bridges to partially include residues near or including Gly-60 in the first loop. The function of this region in Factor IX is unknown but its threedimensional structure has been approximated through an assumed homology of disulfide bond placement with epidermal growth factor as described by Cooke et al. (27) and Montelione et al. (28) . Residues Of interest from these studies, two of the three mutations (B and C) were at CpG dinucleotides which are considered to be mutation hot spots in mammals (33) . The mechanism of this phenomenon is speculated to involve methylation followed by deamination of the cytosine residue resulting in the formation of thymine. This type of mutation leads to a G to A transition in the complimentary strand (in these cases, the sense strand) and is found in nearly half of the reported point mutations in the Factor IX genes of patients with hemophilia B.
The strategy of using selective amplification and DNA sequencing based on immunochemical sub-localization has been demonstrated as an effective method to identify gene mutations in these patients with hemophilia B. The possibility exists that the defects identified, particularly in patients B and C, might be incidental to the hemophilia, as the functional importance of the residues involved has not been demonstrated. The lack of altered reactivity in the immunoassays of Factor IX from over 100 normal males and other hemophilic patients, however, excludes all but rare polymorphisms as an alternative explanation for the findings. Patient A had a defect in what is predicted to be a critical Gla residue (24) . Furthermore, defects in B and C were present in more than one family (in the case of B-1 vs. B-2 in families with a different Factor IX polymorphism), further reducing the probability that the defect is unrelated to hemophilia from about 1 in 100 to 1 in 10,000 or less. Finally, experience locally and in the literature has not shown these single-based transitions in several hemophilic or normal genes that have been cloned and sequenced for all coding and splice junction regions.
A similar strategy should apply to other genetic defects, such as milder forms of hemophilia A. There the gene is much larger and the epitopes for several MAbs have been localized (e.g., reference 34). It would first be necessary to screen affected individuals' plasmas with specific immunoassays.
